Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
about
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients.Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatmTumour-targeted chemotherapy with immunoconjugates of calicheamicin.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Monoclonal antibody-based therapeutics for leukemia.The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials.Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Outcome of older patients with acute myeloid leukemia in first relapse.Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies.Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.Applications of monoclonal antibodies for the treatment of hematological malignancies
P2860
Q33412354-C5BC4D0B-7808-4220-B2EB-294A732D0FDCQ33418153-F87C5BDD-CAAA-46CC-82F2-02FA7619935FQ35125876-74F0C439-5B41-4C2A-B40A-F711343BA9C1Q35566338-A894744E-11BD-41E5-A79F-02AF8F7E2942Q35873771-416BB8CD-0C9A-4D52-8BE6-915D950B6CB3Q36367816-8E9DCE71-F06B-47C0-A7B7-0CD3B118DD54Q36739759-9C720549-AD9D-4FEA-9683-0DEE9A4E1B92Q36832124-7F7E27A3-2692-4C3B-9041-549E9EA54A62Q37026605-72BC8C60-4697-4386-A563-036241BF5D44Q37199950-001D0238-549D-4C9F-923D-727D503F7EC9Q37676299-71F872C1-DC39-412E-A337-19D4E7E64AEEQ37910260-8F170C6B-49E5-4A3D-8E7F-C9C73AA0DED6Q38109541-2AF7E729-9961-4635-939C-8CD0C3756532Q39405204-2106B377-4701-4FD3-951D-EDB030C67D40Q40552183-7F4CE43A-EDFC-4249-8460-F405CF418D4BQ42357653-C028EEF2-E4F3-42E6-B3EE-8B598994579FQ43492386-2D0AEC32-1099-47BF-ABA0-51E9DC0BB801Q44209876-2BAD2AF3-2F46-454B-A9C8-CAAFA2D0E512Q44462005-F9939CCE-9452-4242-BD83-A89236A04DA9Q46966671-AC23F3A5-BB7B-4B28-9682-9AF44727D088Q47929658-2CBC135F-9E2D-443F-B5B1-E9EABF3F0816Q57904664-B7C65A0F-7FC8-431C-8325-38A0E72ADEA5
P2860
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@en
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@nl
type
label
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@en
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@nl
prefLabel
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@en
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@nl
P2093
P50
P1476
Pilot study of Mylotarg, idaru ...... lapsed acute myeloid leukemia.
@en
P2093
Deborah Thomas
Elihu Estey
Francis J Giles
Yesid Alvarado
P2888
P356
10.1007/S00280-002-0546-Z
P50
P577
2002-11-13T00:00:00Z